Advancing Pandemic and Seasonal Influenza Vaccine Preparedness and Response

Harnessing Lessons from the Efforts Mitigating the COVID-19 Pandemic

 

While the world responds to the COVID-19 pandemic, novel influenza viruses continue to be a constant pandemic threat. These viruses, which could appear at any time, can lead to circumstances and ramifications similar to or worse than the current experiences resulting from the COVID-19 pandemic. Both domestic and global efforts, such as the U.S. National Influenza Vaccine Modernization Strategy 2020-2030 and the WHO Global Influenza Strategy 2019-2030, have called for the development of more effective influenza vaccines complemented by modern, adaptable manufacturing technologies that can scale production and meet demand during a pandemic.

The global response to COVID-19 has pushed the boundaries on what is possible for rapid pandemic response in several areas, including vaccine research, development, manufacturing, equitable distribution, allocation, and administration. These unprecedented actions could inform and advance future pandemic and seasonal influenza vaccine preparedness efforts. 

Objective

 

The National Academy of Medicine has established an International Committee (IC) in coordination with the U.S. Health and Human Services Office of Global Affairs (OGA) to inform and facilitate its efforts to advance global influenza pandemic preparedness. This International Committee will provide the OGA an iterative, interactive, multi-disciplinary, expert-informed process for assessing the global impact that capabilities, technologies, processes, and policies developed for COVID-19 could have on pandemic and seasonal influenza global preparedness and response, especially regarding vaccine development.

The NAM International Committee will convene domestic and international experts from across sectors (e.g., government, academia, industry, civil society, international public health organizations) and a variety of disciplines (e.g., global public health; infectious disease prevention; influenza vaccine research, development, and manufacturing; pandemic preparedness and response; virology, and immunology).

The IC will take a comprehensive approach to explore the current state of the art and provide recommendations to improve the global design, composition, clinical trials, production, scale-up, regulatory approval, distribution of influenza vaccines, and post-approval surveillance for adverse events. These recommendations will be developed by four concurrent National Academies consensus study committees and released as four consensus reports.

 

International Committee
  • Martin Friede, PhD (co-chair) | Unit Lead, World Health Organization

  • Prashant Yadav, PhD, MBA (co-chair)  | Senior Fellow, Center for Global Development

  • Ripley Ballou, MD | Principle Investigator, ADVANCE Program, IAVI

  • Norman W. Baylor, PhD | President and Chief Executive Officer, Biologics Consulting

  • Thomas Beat Cueni, MS | Director-General, International Federation of Pharmaceutical Manufacturers & Associations

  • Keiji Fukuda, MD, MPH | Director and Clinical Professor, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong

  • Patricia Jannet Garcia, MD, PhD, MPH | Professor, School of Public Health and Administration, Cayetano Heredia University

  • Anuradha Gupta, MBA | Deputy Chief Executive Officer, Gavi, The Vaccine Alliance

  • Richard Hatchett, MD | Chief Executive Officer, CEPI

  • Daniel B. Jernigan, MD, MPH | Director, Influenza Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention; Captain, USPHS (RET)

  • Etleva Kadilli, MSc | Director, Supply Division, UNICEF

  • Lawrence Kerr, PhD | Director, Pandemics and Emerging Threats. U.S. Department of Health & Human Services

  • Heidi J. Larson, PhD | Director, Vaccine Confidence Project, London School of Hygiene & Tropical Medicine

  • Peter Sands, MPA | Executive Director, The Global Fund to Fight AIDS, Tuberculosis, and Malaria

  • John Simpson, MBBS, MFPHM | Head, Emergency Response Department; Deputy Director, Health Protection Directorate, Public Health England

  • Kanta Subbarao, MBBS, MPH | Director, WHO Collaborating Centre for Reference and Research on Influenza, Melbourne

  • Beverly Ann Taylor, BSc, PhD | Head of Influenza Scientific Affairs, WHO; IFPMA Lead, Seqirus Vaccines

Sponsor
  • U.S. Department of Health & Human Services Office of Global Affairs
Staff
  • Morgan Kanarek | Chief of Staff
  • Jarrett Nguyen | Program Specialist
  • Julie Pavlin | Senior Board Director

Join Our Community

Sign up for NAM email updates